Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

SHSE:688266 Stock Report

Market Cap: CN¥16.1b

Suzhou Zelgen BiopharmaceuticalsLtd Future Growth

Future criteria checks 5/6

Suzhou Zelgen BiopharmaceuticalsLtd is forecast to grow earnings and revenue by 127.3% and 59.6% per annum respectively. EPS is expected to grow by 125.5% per annum. Return on equity is forecast to be 15.7% in 3 years.

Key information

127.3%

Earnings growth rate

125.5%

EPS growth rate

Biotechs earnings growth42.6%
Revenue growth rate59.6%
Future return on equity15.7%
Analyst coverage

Low

Last updated10 Dec 2024

Recent future growth updates

Recent updates

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors

Nov 27
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors

Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates

Sep 11
Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates

What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates

May 08
What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up

Mar 06
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up

Earnings and Revenue Growth Forecasts

SHSE:688266 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,894364223074
12/31/20251,18953-263-924
12/31/2024615-187-297-2154
9/30/2024488-174-2263N/A
6/30/2024407-231-6914N/A
3/31/2024387-261-186-113N/A
12/31/2023386-279-295-233N/A
9/30/2023387-296-377-319N/A
6/30/2023417-325-419-345N/A
3/31/2023367-395-423-341N/A
12/31/2022302-457-459-370N/A
9/30/2022290-522-499-407N/A
6/30/2022253-521-490-399N/A
3/31/2022234-491-494-411N/A
12/31/2021190-451-525-455N/A
9/30/202198-384-518-449N/A
6/30/202170-368-465-400N/A
3/31/202128-337-435-370N/A
12/31/202028-319-402-344N/A
9/30/202028-292-318-271N/A
6/30/2020N/A-249-276-250N/A
3/31/2020N/A-354-234-215N/A
12/31/2019N/A-462-196-180N/A
9/30/2019N/A-747-166-155N/A
12/31/20181-440-124-112N/A
12/31/2017N/A-146N/A-108N/A
12/31/20160-128N/A-57N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688266 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: 688266 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 688266 is expected to become profitable in the next 3 years.

Revenue vs Market: 688266's revenue (59.6% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 688266's revenue (59.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688266's Return on Equity is forecast to be low in 3 years time (15.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 09:56
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyu HeChina International Capital Corporation Limited
Shitong HanCitic Securities Co., Ltd.
Yinhao TangCitic Securities Co., Ltd.